Skip to content

Released May 12, 2026, after the close

10-Q filed May 12, 2026, 42 days after period end · 0001390478-26-000008

Q1 2026 · 10-Q
Revenue—
Net Income-$8.41MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.05N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$9,252,000N/M
Operating Cash Flow-$8,846,000N/M

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Revenue———$0.00
Net Income-$8.41M-$5.81M-$9.57M-$11.10M
EPS Diluted-$0.05-$0.07-$0.21-$0.47

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR